ACT 101

Drug Profile

ACT 101

Alternative Names: ACT-101

Latest Information Update: 02 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Alpha Cancer Technologies
  • Class Recombinant proteins
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Myasthenia gravis
  • New Molecular Entity No

Highest Development Phases

  • Phase I Inflammatory bowel diseases; Multiple sclerosis; Myasthenia gravis; Thyroiditis

Most Recent Events

  • 17 Oct 2017 Phase-I clinical trials in Inflammatory bowel disease in USA (PO)
  • 17 Oct 2017 Phase-I clinical trials in Multiple sclerosis in USA (PO)
  • 17 Oct 2017 Phase-I clinical trials in Myasthenia gravis in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top